慢性淋巴细胞白血病及部分淋巴瘤治疗迎来一个崭新时代：第55届美国血液学会年会报道

A new era in the treatment of chronic lymphocytic leukemia and a part of lymphoma： reports in the 55th ASH annual meeting

第55届美国血液学会（ASH）年会报道了有关慢性淋巴细胞白血病（CLL）和部分淋巴瘤的多项新的靶向治疗药物,这些药物多靶向于B细胞不同的信号转导通路关键靶点.尽管这些靶向药物单独应用并没有提高CLL的疗效,但多项临床试验结果显示联合治疗明显提高了CLL的疗效及延长了CLL患者的无进展生存时间.因此,专家们认为靶向药物的联合治疗和序贯治疗将开启一个CLL治疗的新时代.文章仅就这些最新进展与国内读者共享.

In this year,ASH annual meeting reported several new targeting therapeutic drugs for chronic lymphocytic leukemia （CLL） and a part of lymphoma.Those drugs focus on some key targets in the signal transductional pathway of B cells.Although these targeting drugs individually did not improve the complete remission rate of CLL,but several clinical trial results showed that the combination therapy of those drugs with other drugs significantly improved the efficacy of CLL,and prolonged the progression-free survival of CLL patients.Therefore,experts believe that combination therapy and sequential therapy will start a new era in the treatment of CLL.This paper will share only the latest advances in the treatment of CLL and parts of lymphoma with domestic readers.